Literature DB >> 29299452

Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria.

Laura J Craven1,2, Michael Silverman1,2,3, Jeremy P Burton1,2,4.   

Abstract

Entities:  

Year:  2017        PMID： 29299452      PMCID： PMC5750285          DOI： 10.21037/atm.2017.10.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  16 in total

Review 1.  An evidence-based position statement on the management of irritable bowel syndrome.

Authors:  Lawrence J Brandt; William D Chey; Amy E Foxx-Orenstein; Lawrence R Schiller; Philip S Schoenfeld; Brennan M Spiegel; Nicholas J Talley; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

2.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

3.  An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

Authors:  Ian B Jeffery; Paul W O'Toole; Lena Öhman; Marcus J Claesson; Jennifer Deane; Eamonn M M Quigley; Magnus Simrén
Journal:  Gut       Date:  2011-12-16       Impact factor: 23.059

4.  The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects.

Authors:  I Rangel; J Sundin; S Fuentes; D Repsilber; W M de Vos; R J Brummer
Journal:  Aliment Pharmacol Ther       Date:  2015-09-17       Impact factor: 8.171

5.  Establishing a Fecal Microbiota Transplant Service for the Treatment of Clostridium difficile Infection.

Authors:  Samuel P Costello; Emily C Tucker; Justin La Brooy; Mark N Schoeman; Jane M Andrews
Journal:  Clin Infect Dis       Date:  2015-11-30       Impact factor: 9.079

6.  Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome.

Authors:  Evangelos Giamarellos-Bourboulis; Jie Tang; Emmannouil Pyleris; Aikaterini Pistiki; Charalambos Barbatzas; Jordan Brown; Clarence C Lee; Timothy T Harkins; Gene Kim; Stacy Weitsman; Gillian M Barlow; Vincent A Funari; Mark Pimentel
Journal:  Scand J Gastroenterol       Date:  2015-04-11       Impact factor: 2.423

7.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 8.  Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals.

Authors:  T T Kararli
Journal:  Biopharm Drug Dispos       Date:  1995-07       Impact factor: 1.627

Review 9.  Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis.

Authors:  Guillaume Fond; Anderson Loundou; Nora Hamdani; Wahid Boukouaci; Aroldo Dargel; José Oliveira; Matthieu Roger; Ryad Tamouza; Marion Leboyer; Laurent Boyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-04-06       Impact factor: 5.270

10.  Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.

Authors:  Ian M Carroll; Tamar Ringel-Kulka; Temitope O Keku; Young-Hyo Chang; Christopher D Packey; R Balfour Sartor; Yehuda Ringel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-07       Impact factor: 4.052
View more
  1 in total

Review 1.  Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Roberta Forlano; Mathuri Sivakumar; Benjamin H Mullish; Pinelopi Manousou
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.